VARIOUS measures have been proposed to reduce the endogenous production of oxalic acid in patients with primary hyperoxaluria; these include the oral administration of sodium benzoate, 1 ...

He ordered additional tests, which found elevated levels of oxalate in Jack’s urine and blood. Subsequent genetic testing confirmed the diagnosis: primary hyperoxaluria type 1 (PH1) – a rare, ...

Jack had a history of periodic stomach and bladder pain, unexplained vomiting and susceptibility to dehydration and fatigue in hotter weather, but in isolation, none of these symptoms seemed serious ...

The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder. Oxlumo (lumasiran ...

Controlling the dissolved oxygen in bioreactors sets the stage for developing new treatments for liver disease.

Since then, Alnylam has claimed approval for two more RNAis, Givlaari (givosiran) for acute hepatic porphyria (AHP) and Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1). RNAi uses small ...

Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States The Cancer Institute of New Jersey, New ...